The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ERIC 2026 | Multiclonal origins and clonal evolution in CLL
Elias Campo, MD, PhD, University of Barcelona, Barcelona, Spain, discusses the multiclonal origins of chronic lymphocytic leukemia (CLL) and how clonal selection shapes disease evolution. Prof. Campo highlights the progressive selection of dominant clones during disease progression and explores how understanding the biological mechanisms driving this process could help identify opportunities for earlier intervention and prevention of aggressive disease. This interview took place at the 2026 ERIC International Meeting in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
